Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
7,113 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01793168 | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford(CoRDS) | recruiting | — | 20,000 | Sanford HealthOTHER | 2 | May 29, 2025 | clinicaltrials |
| NCT04824027 | Breast Elasticity Imaging During Neoadjuvant Chemotherapy | recruiting | N/A | 50 | Columbia UniversityOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06049355 | EMBRACE: Exercising Together | recruiting | Phase 2 | 400 | OHSU Knight Cancer InstituteOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT05870800 | Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER(NICER) | recruiting | Phase 2 | 28 | Baylor College of MedicineOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT03977402 | Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer(TCCP) | recruiting | — | 47,500 | New Mexico Cancer Research AllianceOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT05541822 | To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation | recruiting | Phase 2 | 178 | Abion IncINDUSTRY | 3 | May 22, 2025 | clinicaltrials |
| NCT06016179 | Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer(RIOT2) | recruiting | Phase 1 | 12 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT05915442 | Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer(SBRT-AMICO) | recruiting | Phase 2 | 23 | Catherine SpinaOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT05914766 | An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer(PATHWAYS) | recruiting | N/A | 80 | Massachusetts General HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT05970497 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 240 | Krystal Biotech, Inc.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT06744296 | Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck(MRD-DUCHESS) | recruiting | — | 75 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT05380349 | Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma | recruiting | Early Phase 1 | 10 | Swedish Medical CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05394831 | A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC | recruiting | Phase 1 / Phase 2 | 150 | J Ints BioINDUSTRY | 3 | May 16, 2025 | clinicaltrials |
| NCT06706752 | A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy | recruiting | N/A | 30 | Sutter HealthOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06914648 | The Dragon PLC Trial (DRAGON-PLC) | recruiting | N/A | 358 | Maastricht UniversityOTHER | 12 | May 15, 2025 | clinicaltrials |
| NCT06972628 | Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 | recruiting | Phase 2 | 30 | Ebrahim S DelpassandOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06165419 | Definitive Radiation for High-Risk Spine Metastases | recruiting | Phase 2 | 26 | Stony Brook UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT04254419 | Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells | recruiting | Phase 1 | 18 | Nationwide Children's HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06747364 | Phosphatidylethanol and Other Ethanol Consumption Markers | recruiting | N/A | 80 | The University of Texas Health Science Center at San AntonioOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06634394 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | recruiting | Phase 1 | 39 | Aptevo TherapeuticsINDUSTRY | 1 | May 11, 2025 | clinicaltrials |
| NCT06136546 | Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab | recruiting | Phase 2 | 100 | Massachusetts General HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06140927 | Effect of Ketamine on Intraoperative Motor Evoked Potentials | recruiting | Phase 3 | 20 | University of California, San FranciscoOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT03964480 | Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | recruiting | — | 1,000 | Associazione Angela Serra per la ricerca sul cancroOTHER | 4 | May 6, 2025 | clinicaltrials |
| NCT04515836 | Olaparib in Patients With HRD Malignant Mesothelioma | recruiting | Phase 2 | 56 | University of ChicagoOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05234177 | Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays | recruiting | — | 300 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT03509961 | The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | recruiting | Phase 2 | 95 | Pediatric Transplantation & Cellular Therapy ConsortiumOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03898596 | Umbilical Vessel Catheterization Under ECG Monitoring and Guidance | recruiting | N/A | 150 | Stanford UniversityOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05836688 | A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors | recruiting | N/A | 250 | University of California, IrvineOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05386615 | Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids | recruiting | — | 200 | InSightecINDUSTRY | 2 | Apr 30, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT03824145 | Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer(EDC) | recruiting | N/A | 176 | Medical College of WisconsinOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06945315 | SAFE Nerve Sparing Guided by Micro-ultrasound (MUS) | recruiting | Phase 3 | 196 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT03571568 | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | recruiting | Phase 1 / Phase 2 | 140 | BioInvent International ABINDUSTRY | 6 | Apr 24, 2025 | clinicaltrials |
| NCT06046495 | A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer | recruiting | Phase 1 | 81 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06297941 | Study of REM-422 in Patients With AML or Higher Risk MDS | recruiting | Phase 1 | 100 | Remix TherapeuticsINDUSTRY | 2 | Apr 23, 2025 | clinicaltrials |
| NCT05956457 | PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma | recruiting | N/A | 100 | Pack HealthINDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT05239338 | Preserving Fertility After Colorectal Cancer Study(PREFACE) | recruiting | — | 1,000 | Andreana Holowatyj, PhD, MSCIOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT05266898 | Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV(AGO-Gard) | recruiting | Phase 4 | 250 | Louisiana State University Health Sciences Center in New OrleansOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT05288777 | Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer(Breast53) | recruiting | Phase 2 / Phase 3 | 45 | University of VirginiaOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT05734430 | Genetics of Appendix Cancer Study(GAP) | recruiting | — | 700 | Andreana Holowatyj, PhD, MSCIOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06933758 | Temple Health Chest Initiative (THCI 2.0) | recruiting | — | 1,000 | Temple UniversityOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06462365 | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | recruiting | Phase 1 | 36 | Tr1X, Inc.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT03592472 | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | recruiting | Phase 3 | 413 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 6 | Apr 13, 2025 | clinicaltrials |
| NCT05423691 | Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs(TREG108) | recruiting | Phase 1 | 24 | Cellenkos, Inc.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06918223 | Assessing Patient Satisfaction and Confidence After Use of Educational Video to Augment Surgical Consent for Thyroid Surgery(TISCAV) | recruiting | N/A | 60 | Thomas Jefferson UniversityOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT05564936 | The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis | recruiting | N/A | 144 | Ad scientiamOTHER | 2 | Apr 11, 2025 | clinicaltrials |
| NCT04215809 | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL | recruiting | Phase 1 | 144 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Apr 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials